Literature DB >> 34208874

ACO (Asthma-COPD Overlap) Is Independent from COPD: The Case in Favour.

Peter M A Calverley1, Paul Phillip Walker2,3.   

Abstract

Over the last decade interest has been shown in people with symptomatic lung disease who have features both of COPD and asthma. In this review we examine how COPD and asthma are defined and examine clinical characteristics of people defined by researchers as having asthma-COPD overlap (ACO). We look at pathological and physiological features along with symptoms and consider the impact of each diagnosis upon therapeutic management. We highlight challenges in the diagnosis and management of airway disease and the various phenotypes that could be part of ACO, in so doing suggesting ways for the clinician to manage patients with features of both asthma and COPD.

Entities:  

Keywords:  COPD; asthma; asthma–COPD overlap; bronchodilator reversibility; respiratory pathophysiology

Year:  2021        PMID: 34208874     DOI: 10.3390/diagnostics11071189

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  90 in total

Review 1.  The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases?

Authors:  Eric D Bateman; Helen K Reddel; Richard N van Zyl-Smit; Alvar Agusti
Journal:  Lancet Respir Med       Date:  2015-08-05       Impact factor: 30.700

2.  Discriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization and Mortality.

Authors:  Surya P Bhatt; Pallavi P Balte; Joseph E Schwartz; Patricia A Cassano; David Couper; David R Jacobs; Ravi Kalhan; George T O'Connor; Sachin Yende; Jason L Sanders; Jason G Umans; Mark T Dransfield; Paulo H Chaves; Wendy B White; Elizabeth C Oelsner
Journal:  JAMA       Date:  2019-06-25       Impact factor: 56.272

3.  Blood eosinophils as a marker of response to inhaled corticosteroids in COPD.

Authors:  Neil C Barnes; Raj Sharma; Sally Lettis; Peter M A Calverley
Journal:  Eur Respir J       Date:  2016-02-25       Impact factor: 16.671

4.  The natural history of chronic airflow obstruction.

Authors:  C Fletcher; R Peto
Journal:  Br Med J       Date:  1977-06-25

Review 5.  Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome: Nothing New Under the Sun.

Authors:  Nirupama Putcha; Robert A Wise
Journal:  Immunol Allergy Clin North Am       Date:  2016-08       Impact factor: 3.479

6.  Asthma-COPD Overlap-A Discordance Between Patient Populations Defined by Different Diagnostic Criteria.

Authors:  Adam Barczyk; Marta Maskey-Warzęchowska; Katarzyna Górska; Marek Barczyk; Krzysztof Kuziemski; Paweł Śliwiński; Halina Batura-Gabryel; Robert Mróz; Aleksander Kania; Andrzej Obojski; Maciej Tażbirek; Natalia Celejewska-Wójcik; Katarzyna Guziejko; Beata Brajer-Luftmann; Damian Korzybski; Iwona Damps-Kostańska; Rafał Krenke
Journal:  J Allergy Clin Immunol Pract       Date:  2019-04-26

7.  Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group.

Authors:  J Vestbo; E Prescott; P Lange
Journal:  Am J Respir Crit Care Med       Date:  1996-05       Impact factor: 21.405

8.  The association between childhood asthma and adult chronic obstructive pulmonary disease.

Authors:  Andrew Tai; Haily Tran; Mary Roberts; Nadeene Clarke; John Wilson; Colin F Robertson
Journal:  Thorax       Date:  2014-03-19       Impact factor: 9.139

9.  Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease.

Authors:  Paul Albert; Alvar Agusti; Lisa Edwards; Ruth Tal-Singer; Julie Yates; Per Bakke; Bartolome R Celli; Harvey O Coxson; Courtney Crim; David A Lomas; William Macnee; Bruce Miller; Stephen Rennard; Edwin K Silverman; Jørgen Vestbo; Emiel Wouters; Peter Calverley
Journal:  Thorax       Date:  2012-06-13       Impact factor: 9.139

10.  ACO: Time to move from the description of different phenotypes to the treatable traits.

Authors:  Nuria Toledo-Pons; Job F M van Boven; Miguel Román-Rodríguez; Noemí Pérez; Jose Luis Valera Felices; Joan B Soriano; Borja G Cosío
Journal:  PLoS One       Date:  2019-01-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.